|
Orthologous residues
|
|
BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site, western blotting
|
|
Relevant cell lines - cell types - tissues:
FL5.12 (lymphoid)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Comments:
PKA inhibitor blocks endogenous kinase that phosphorylates S112.
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKACA (mouse)
|
pharmacological inhibitor of upstream enzyme, co-immunoprecipitation
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
IL-3
|
|
|
|
increase
|
|
|
H-89, IL-3
|
IL-3
|
|
|
inhibit treatment-induced increase
|
|
|
IL-3, LY294002
|
IL-3
|
|
|
inhibit treatment-induced increase
|
|
|
IL-3, PD98059
|
IL-3
|
|
|
inhibit treatment-induced increase
|
|
|
IL-3, 8-Rp-cAMP
|
IL-3
|
|
|
inhibit treatment-induced increase
|
|
|
IL-3, PD98059, LY294002
|
IL-3
|
|
|
augment treatment-induced decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization
|
|
Effect of modification (process):
apoptosis, altered
|
|
Comments:
Bad is phosphoryated by PKA associated with mitochondrial membrane fraction.
|
